| Item 7.01 | Regulation FD Disclosure. |
On April 23, 2024, Day One Biopharmaceuticals, Inc. (the “Company”) issued a press release titled “Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor.” A copy of the press release is attached hereto as Exhibit 99.1.
On April 24, 2024, the Company also updated its corporate presentation. A copy of the updated presentation is attached as Exhibit 99.2 to this report.
The information in this Item 7.01, including Exhibits 99.1 and 99.2 to this report, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The information contained in this Item 7.01 and in the accompanying Exhibits 99.1 and 99.2 shall not be incorporated by reference into any other filing under the Exchange Act or under the Securities Act, except as shall be expressly set forth by specific reference in such filing.
On April 23, 2024, the Company announced that the U.S. Food and Drug Administration (the “FDA”) approved OJEMDA (a tablet formulation and powder solution formulation of tovorafenib) for the treatment of patients of 6 months of age and older with relapsed or refractory low-grade glioma (“pLGG”) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. The indication was approved under accelerated approval based on response rate and duration of response. With the approval, the Company received a rare pediatric disease priority review voucher from the FDA.
The accelerated approval of OJEMDA is based on data from the Company’s pivotal open-label Phase 2 FIREFLY-1 trial, which enrolled a total of 137 relapsed or refractory BRAF-altered pLGG patients across two study arms. Arm 1, which accrued 77 patients, was used for the efficacy analyses. Arm 2 provided additional safety data from an incremental 60 patients and was initiated to enable access to tovorafenib once Arm 1 had fully accrued. Details of this trial were presented in November 2023 at the Society for Neuro-Oncology meeting through two oral plenary presentations and in parallel through a publication in Nature Medicine.
The approval of OJEMDA was based, in part, on the major efficacy outcome measure of overall response rate (“ORR”), defined as the proportion of patients with complete response, partial response (“PR”), or minor response (“MR”) by independent review based on Response Assessment in Pediatric Neuro-Oncology Low-Grade Glioma (“RAPNO LGG”).
In Arm 1, data from the 76 RAPNO LGG evaluable patients include:
| | • | | A best ORR of 51% (95% CI: 40 - 63), which included 28% PRs and 11% MRs. |
| | • | | The ORR for OJEMDA was 52% among the 64 patients with BRAF fusions or rearrangements and 50% for the 12 patients with a BRAF V600 mutation. |
| | • | | The ORR was 49% among the 45 patients who had received a prior MAPK-targeted therapy, and 55% among the 31 patients who had not received a prior MAPK-targeted therapy. |
| | • | | As of the June 5, 2023 data cutoff, the median duration of response by RAPNO LGG was 13.8 months (95% CI: 11.3, not estimable). In addition, 66% of patients remained on study and continue on treatment as of this date. |
| | • | | The median time to response, following initiation of treatment, with OJEMDA was 5.3 months (range 1.6, 11.2). |
| | • | | Based on RANO LGG criteria, the ORR was 53% [95% CI: (41, 64)]. |
The safety of OJEMDA was evaluated in 137 patients with relapsed or refractory pLGG, with the majority of adverse events being Grade 1 or Grade 2. The most common side effects were rash, hair color changes, tiredness, viral infection, vomiting, headache, fever, dry skin, constipation, nausea, acne and upper respiratory tract infection.
The Company has set a wholesale acquisition cost for a 28-day supply of OJEMDA at $33,916.
